The financial burden of providing healthcare and the rising cost of the most innovative medicines have pressured government healthcare budgets and highlight the need for payers to operate under a disciplined financial framework. The use of health technology assessment (HTA) is one of the main ways that payers can adopt a system for efficiently allocating their scarce financial resources and provide a framework for the rational use of expensive drugs. The implementation of HTA practices and policies is increasing around the world as more countries grapple with the issue of providing healthcare to a growing number of their citizens. This need is particularly acute in many emerging markets, where access to innovative, branded medicines is limited among the broader population.

Although certain lessons can be applied from recent experiences in the established markets, there are also many unique barriers in the emerging markets that have hampered the full implementation of HTA. The focus of this report will be on recent HTA developments and their implications in several of the major emerging markets in Latin America, Asia-Pacific, and the Middle East, as we apply some lessons learned from the pioneers in this field.

Questions Answered in This Report:

  • New HTA guidelines, policies, and practices are in place in an increasing number of the world’s developing pharmaceutical markets. This approach is prevalent in many countries where the government is attempting to broaden access to innovative medicines to its population. What are the new product opportunities and regulatory challenges that multinational pharmaceutical companies will face in dealing with an increasing number of HTA authorities around the world?

  • Significant obstacles remain to the implementation of HTA in many emerging markets. Access to innovative medicines in emerging markets is hampered by limited insurance coverage, scarce financial resources, and fast-growing populations. Difficulties also exist in reaching large segments of the population located in rural areas. Which countries have the most centralized healthcare structures in place, and which are the most fragmented healthcare markets? Where is the need for local patient data the most crucial?

  • Even in developed markets, significant variations exist between HTA requirements and practices in each country. Which HTA agencies have been most influential in shaping the systems in developing markets? How will HTA evolve in these new markets?

Scope:

Markets covered: Argentina, Australia, Brazil, Canada, Chile, China, Colombia, France, Germany, India, Indonesia, Italy, Japan, Mexico, Philippines, Poland, Russia, Saudi Arabia, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Turkey, United Kingdom, and Vietnam.

Primary research: Three interviewed experts: Coordinator of Pharmaceutical Assistance Program, Brazil, State Health Department, Consultant, Brazilian Ministry of Health, Oncologist, Key Opinion Leader, Brazil

Author(s): Michael Latwis, M.B.A.